Please login to the form below

Not currently logged in
Email:
Password:

Boehringer's afatinib moves into phase III trials for head and neck cancer

Drug is potential challenge to ImClone, Bristol-Myers Squibb and Merck Serono’s Erbitux

Boehringer Ingelheim has started two phase III clinical trials of afatinib in head and neck cancer.

The studies will evaluate the drug in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease.

They follow positive phase II results, which compared afatinib to ImClone, Bristol-Myers Squibb and Merck Serono's Erbitux (cetuximab).

“Currently, approximately 50 per cent of patients with locally advanced head and neck cancer will have a recurrence and there is an urgent need for more treatment options” said Dr Ezra Cohen, associate professor of medicine at the University of Chicago Medical Center, who will be part of the research team.

“We hope potential new treatments such as afatinib will increase the effective options for patients with head and neck cancer.”

The move expands the clinical trial programme for the drug, which is currently being investigated for use in the treatment of non-small cell lung cancer (NSCLC).

However, in a phase II/III study in NSCLC afatinib did not achieve the primary endpoint of extending survival, even though the drug was associated with objective improvements.

These included delayed disease progression and improvements in cancer-related symptoms in a population which currently has no other treatment option.

The drug is a next generation tyrosine kinase inhibitor, which targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2).

Mutations affecting EGFR expression can lead to tumour growth, with the aim of EGFR inhibitors to control this expression.

Currently approved therapies targeting EGFR are Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib) as well as Erbitux, which won US approval in advanced head and neck cancer in November. However, many patients develop resistance to these treatments.

Afatinib and Pfizer's dacomitinib, which is in phase II trials for head and neck cancer, are aiming to provide alternative treatment options.

26th January 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Door Unlimited

Red Door Unlimited is the health and wellbeing communications consultancy that lives and breathes originality and is built on `firsts'....

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....